Claims

1. Use of a pharmaceutical composition comprising desPro^{36}Exendin-4(1-39)-Lys$_6$-NH$_2$ or/and a pharmaceutically acceptable salt thereof in the manufacture of a medicament for reducing postprandial plasma glucose concentration in a diabetes type 2 patient, wherein the diabetes type 2 patient to be treated has a 2 hours postprandial plasma glucose concentration of at least 14 mmol/L and a body mass index of at least 30 kg/m^2, wherein the patient to be treated does not receive an antidiabetic treatment.

2. The use according to claim 1, wherein the patient to be treated is an adult subject.

3. The use of any of the preceding claims, wherein in the patient to be treated, diabetes mellitus type 2 has been diagnosed at least 1 year or at least 2 years before onset of therapy.

4. The use of any of the preceding claims, wherein the patient to be treated has a HbA$_{1c}$ value of about 7 to about 10%.

5. The use of any of the preceding claims, wherein the patient to be treated has a fasting plasma glucose concentration of at least 8 mmol/L.

6. The use of any of the preceding claims, wherein the desPro^{36}Exendin-4(1-39)-Lys$_6$-NH$_2$ or/and the pharmaceutically acceptable salt thereof is to be administered parenterally.

7. The use according to any of the preceding claims, wherein the pharmaceutical composition is prepared for administration of desPro^{36}Exendin-4(1-39)-Lys$_6$-NH$_2$ or/and the pharmaceutically acceptable salt thereof in a daily dose selected from the range of 10 µg

to 20 µg.

8. The use according to any of the preceding claims, wherein the pharmaceutical composition is prepared for once daily administration.

9. The use according to any of the preceding claims, wherein the pharmaceutical composition is further comprising pharmaceutically acceptable carriers, adjuvants, or/and auxiliary substances.